Evidence map›Paper›PMID 41029272›Full record

ArticleBMC cancer2025

Adverse events associated with Lutetium-177-PSMA-617 (Pluvicto

Yongchen Jin, Yishan Zhang, Mingshuai Wang, Xiaoxuan Bai, Hao Ping, Nianzeng Xing

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yongchen JinDepartment of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
Yishan ZhangDepartment of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
Mingshuai WangDepartment of Urology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Xiaoxuan BaiDepartment of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
Hao PingDepartment of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China. pinghaotrh@ccmu.edu.cn.
Nianzeng XingDepartment of Urology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. xingnianzeng@126.com.

Funding

Capital's Funds for Health Improvement and Research No. 2024-2-2059National Natural Science Foundation of China No. 82072833 and No. 82272864
6 · The paper itself

Abstract

objectivePluvicto

methodsThe AEs reports suspected primarily of Pluvicto

resultsA total of 7654 patient reports primarily suspected of Pluvicto

conclusionsThe study confirmed many significant AE signals that have been listed in the prescribing information or reported in previous studies. Special attention should be paid to patients over 90Kg. It was recommended that intensified laboratory screening of clinical indexes, implement early neurologic monitoring.

Indexed as

Adverse Drug Reaction Reporting SystemsLutetiumProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantRadiopharmaceuticalsAdolescentAdultAgedAged, 80 and overBayes TheoremFemaleHematologic DiseasesHumansMaleMiddle AgedNervous System DiseasesLutetiumPluvictoProstate-Specific AntigenRadiopharmaceuticalsAdverse eventDisproportionality analysisFAERSLutetium (177Lu) vipivotide tetraxetanLutetium-177-PSMA-617Pluvicto®

Identifiers

PMID41029272
PMCPMC12481865

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.